01st week of 2016 patent applcation highlights part 10 |
Patent application number | Title | Published |
20160000907 | NEOSEPTINS: SMALL MOLECULE ADJUVANTS - A MD-2:TLR4 complex agonist compound is disclosed whose structure corresponds to Formula (I), as defined within. Also disclosed are a method of its preparation and use, as well as a pharmaceutical composition containing the same. | 2016-01-07 |
20160000908 | Siglec-9 Binding Agents - The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods. | 2016-01-07 |
20160000909 | REDUCING SYSTEMIC REGULATORY T CELL LEVELS OR ACTIVITY FOR TREATMENT OF DISEASE AND INJURY OF THE CNS - A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session. | 2016-01-07 |
20160000910 | Monoclonal Antibody - The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD). | 2016-01-07 |
20160000911 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXITY (ADCC) - The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine. | 2016-01-07 |
20160000912 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a proteasome inhibitor for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and a proteasome inhibitor. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and a proteasome inhibitor. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and a proteasome inhibitor. | 2016-01-07 |
20160000913 | TARGETED TREATMENT OF ANEROBIC CANCER - The present invention relates to a pharmaceutical cocktail and methods of treatment involving said cocktail, in particular, a combination of effective amounts of a carbonic anhydrase inhibitor, in combination with effective amounts of an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab for the treatment of cancer. In other embodiments, it relates to compositions and methods of treating cancer involving effective amounts of a carbonic anhydrase inhibitor. Pharmaceutical compositions and methods of treating cancer (eliminating the tumor, shrinking the tumor, prolonging the life of the patient, increasing quality of life by decreasing the grade of adverse events seen with other cancer treatments, and/or preventing/reducing the likelihood of the tumor's metastases) are additional aspects of the present invention. In addition, the present invention may be used to favorably impact the therapeutic result of patients who have not responded to alternative, traditional anti-cancer therapy. | 2016-01-07 |
20160000914 | COMBINATION OF TUMOR-ASSOCIATED SURFACE PROTEIN ANTIGENS AND TUMOR-ASSOCIATED SUGARS IN THE TREATMENT AND DIAGNOSIS OF CANCER - The invention relates to a kit for the combined use for the treatment of cancer patients, which set comprises an antigen of a cellular surface protein, or an antibody directed against the cellular surface protein, and an antigen of an aberrant glycosylation, or an antibody directed against the aberrant glycosylation. This kit is destined both for the immunotherapeutic and the diagnostic application. The invention further relates to a selection method for selecting suitable tumor-specific antigens with the assistance of this kit and corresponding specific antibody preparations. | 2016-01-07 |
20160000915 | CROSSLINKING OF CD22 BY EPRATUZUMAB TRIGGERS BCR SIGNALING AND CASPASE-DEPENDENT APOPTOSIS IN HEMATOPOIETIC CANCER CELLS - Extensive crosslinking of CD22 by plate-immobilized epratuzumab induced intracellular changes in Daudi cells similar to ligating B-cell antigen receptor (BCR) with a sufficiently high amount of anti-IgM. Either treatment leads to phosphorylation of CD22, CD79a and CD79b, along with their translocation to lipid rafts, both of which were needed to induce caspase-dependent apoptosis. Immobilization also induced stabilization of F-actin, phosphorylation of Lyn, ERKs and JNKs, generation of reactive oxygen species (ROS), decrease in mitochondria membrane potential (Δψ | 2016-01-07 |
20160000916 | LOW CONCENTRATION ANTIBODY FORMULATIONS - The present invention is directed formulations for low concentrations of therapeutic proteins and methods of making the same. In one aspect the present invention is directed to a formulation for a therapeutic protein comprising: a) the therapeutic protein; and b) a surfactant; wherein the molar ratio of surfactant to therapeutic protein is at least 100. In another aspect the present invention is directed to a formulation for a therapeutic protein comprising: a) the therapeutic protein; and b) an antioxidant, wherein the molar ratio of antioxidant to therapeutic protein is at least 750. | 2016-01-07 |
20160000917 | HOMEOPATHIC COMPLEX - The present invention is directed to a homeopathic complex for use in the treatment of various diseases or disorders, including use as an anti-infective agent and/or in the regeneration of diseased or damaged tissue. Ideally, the anti-infective homeopathic complex of the invention may comprise a homeopathic tincture or dilutions thereof of Hepar sulphuris calcareum or other similar profiled Calcarea or Sulphur salt or acid, Lachesis muta or other remedy with a similar profile, Mercurius Solubilis or similar mercury containing remedy and Silica or other silica containing compounds. | 2016-01-07 |
20160000918 | SUPRAMOLECULAR MAGNETIC NANOPARTICLES - A supramolecular magnetic nanoparticle (SMNP) can be formed by self-assembly of structural components, binding components, terminating components and at least one magnetic nanoparticle. The SMNP can provide on-demand release of a cargo and act as part of an on-demand drug release system. | 2016-01-07 |
20160000919 | ACID-SUBSTITUTED POLYANILINE-GRAFTED HYDROGEL COPOLYMER AND USE THEREOF - An (acid-substituted polyaniline)-grafted hydrogel copolymer is provided. The (acid-substituted polyaniline)-grafted hydrogel copolymer has a general formula as below: | 2016-01-07 |
20160000920 | HIGH LOAD DISPERSIONS - The present invention relates to the field of carrier and delivery systems for active molecular compounds. In particular, the present invention provides aqueous dispersions for delivery of active molecular compounds. | 2016-01-07 |
20160000921 | CEFTOLOZANE ANTIBIOTIC COMPOSITIONS - This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions. | 2016-01-07 |
20160000922 | FUNCTIONALISED TRIBLOCK COPOLYMERS AND COMPOSITIONS CONTAINING SUCH POLYMERS - Amphiphilic triblock copolymers B-A-B, wherein A is a linear poly(ethylene glycol) block, having a number average molecular weight (M | 2016-01-07 |
20160000923 | DRUG DELIVERY SYSTEM TO INCREASE BIOAVAILABILITY - Disclosed herein are novel methods of treating diseases, novel dosage forms, and novel methods of modulating the pharmacokinetics of active ingredients. | 2016-01-07 |
20160000924 | METHODS FOR PRODUCING A BIODEGRADABLE CHITOSAN COMPOSITIONS AND USES THEREOF - The invention provides improved methods for generating biodegradable chitosan compositions, and therapeutic methods of using such compositions to deliver therapeutic agents. | 2016-01-07 |
20160000925 | Preparations, Methods And Kits Useful For The Treatment Of Cough - The invention relates to a respiratory preparation providing cough relief in a human comprising: a film forming agent; a thickening agent; and the respiratory preparation provides on demand relief. Additionally, the invention relates to a method of providing cough relief in a human comprising: the steps of administering to a human a respiratory preparation comprising: a film forming agent; a thickening agent; and wherein said respiratory preparation provides on demand cough relief as needed. | 2016-01-07 |
20160000926 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS - The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS. | 2016-01-07 |
20160000927 | REVERSIBLE PEGYLATED DRUGS - Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety. | 2016-01-07 |
20160000928 | Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine - The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria | 2016-01-07 |
20160000929 | POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT - The presentinvention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety selected from prostaglandin analogues, β-blockers and mixtures thereof. The present invention also relates to methods for preparing the polymer conjugates using click chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the treatment of glaucoma. | 2016-01-07 |
20160000930 | METHODS AND COMPOSITIONS FOR TARGETING ADIPOSE CELLS IN MAMMALS - Methods and compositions are presented for use in diagnostic, imaging or targeting of therapeutic agents to treat obesity/adiposity-associated disorders, compositions and methods identify and use peptides to selectively target adipose tissue stromal cells in mammals. | 2016-01-07 |
20160000931 | SITE-SPECIFIC INSULIN CONJUGATE - Provided are an insulin conjugate having improved insulin receptor binding affinity and increased activity, in which a non-peptidyl polymer and an immunoglobulin Fc region are site-specifically linked to an amino acid residue of the insulin beta chain excluding the N-terminus thereof via a covalent bond, a long-acting formulation including the same, and a preparation method thereof. The insulin conjugate of the present invention is used to provide an insulin formulation which exhibits a remarkably increased in vivo activity of the peptide. | 2016-01-07 |
20160000932 | MODIFIED Fc MOLECULES - Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them. A DNA encoding the inventive composition of matter, an expression vector containing the DNA, and a host cell containing the expression vector are also disclosed. | 2016-01-07 |
20160000933 | CONJUGATED BIOLOGICAL MOLECULES AND THEIR PREPARATION - Conjugation reagents of formula (1) that form a bridge between two cystein residues derived from the disulfide bond and a two-step process for the preparation of antibody conjugates are disclosed. | 2016-01-07 |
20160000934 | NANOPARTICLES STABILIZED WITH NITROPHENYLBORONIC ACID COMPOSITIONS - Described herein are polymer conjugates comprising a polymer containing a polyol coupled to a polymer containing a nitroboronic acid. | 2016-01-07 |
20160000935 | INCREASING TUMOR OXYGENATION FOR DIAGNOSTIC ASSESSMENTS - A method of assessing the susceptibility of a tumor to reduction in hypoxia, comprising delivering oxygen and CO | 2016-01-07 |
20160000936 | BIOMARKERS FOR INFLAMMATORY DISEASE AND METHODS OF USING SAME - The invention provides methods for predicting the efficacy of anti-TNF and anti-IL-17 combination therapies in the treatment of a subject suffering from inflammatory disease by determining the level LIF, CXCL1, CXCL2, CXCL4, CXCL5, CXCL8, CXCL9, CXCL10, CCL2, CCL23, IL-1β, IL-1Ra, TNF, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IFNγ, CXCR1, CXCR4, CXCR5, GM-CSF, GM-CSFR, G-CSF, G-CSFR protein or nucleic acid, or a homolog, portion or derivative thereof markers in a sample derived from the subject. | 2016-01-07 |
20160000937 | MODULATION OF TELOMERE LENGTH IN TELOMERASE POSITIVE CELLS AND CANCER THERAPY - Induction of telomere shortening, G2 arrest and apoptosis in telomerase positive cancer cells using acyclic nucleoside analogs has been disclosed. In addition, methods for impairment or prevention of tumorigenic telomerase positive cells from having a chance to grow into a tumor and methods for promoting tumor regression (decrease in size of an established tumor) using acyclic nucleoside analogs has been disclosed. | 2016-01-07 |
20160000938 | REAGENT FOR DIAGNOSIS OF OSTEOARTHRITIS COMPRISING PEPTIDE PROBE OF APOPEP-1 - Disclosed is a reagent for diagnosing osteoarthritis or predicting the prognosis of osteoarthritis, the reagent containing a peptide having the amino acid sequence (CQRPPR) of SEQ ID NO: 1 as an active ingredient. The present peptide can be used to accurately diagnose osteoarthritis in its early stage based on the molecular imaging technique. The present peptide has a small molecular weight, and thus has advantages of fast clearance from the blood, effective permeation into the tissue, low immunogenicity, and low-production cost. Further, the present reagent can diagnose osteoarthritis in its early stage in which the destruction of cartilage is in a reversible phase and thus can be recovered to a normal state, thereby significantly contributing to effective treatment of osteoarthritis. | 2016-01-07 |
20160000939 | BIO-COMPATIBLE RADIOPAQUE DENTAL FILLERS FOR IMAGING - Dental contrast formulations (“fillers”) of tailorable X-Ray radiopacity and methods for their use are provided. The disclosed fillers include mixtures of solid particles suspended in a biocompatible fluid. The solid particles contain one or more X-ray radiopaque materials. The biocompatible fluid can also contain one or more soluble X-ray radiopaque components. By controlling the composition of the solid particles, the composition of the biocompatible fluid, and the loading of the solid particles in the biocompatible fluid, the X-ray radiopacity and stability of the filler can be tailored to allow for improved discrimination of the filler within periodontal pockets, relative to adjacent soft tissue and teeth, so that the 3-D shape, volume, and depth of the pocket can be precisely and rapidly determined by X-Ray imaging. | 2016-01-07 |
20160000940 | MIRNA PROFILING COMPOSITIONS AND METHODS OF USE - Disclosed herein is a nanosensor of miRNA activity in a target cell, and methods of use, for detection and diagnostic applications. The nanosensor comprises a delivery particle comprising an iron oxide crystal coated with a polymer; and a sensor oligonucleotide covalently attached to the polymer. The sensor oligonucleotide comprises a seed region, comprising a nucleic acid sequence that is completely complementary to the target miRNA and comprises a cleavage site which can be engaged and cleaved by the target miRNA. | 2016-01-07 |
20160000941 | Semifluorocarbon Compound Containing Contrast Agent - The present invention relates to an aqueous emulsion comprising a) a semifluorinated compound of formula I: CF | 2016-01-07 |
20160000942 | MRI CONTRAST AGENT INCLUDING T1 CONTRAST MATERIAL COATED ON SURFACE OF NANOPARTICLE SUPPORT - The present invention relates to a magnetic resonance imaging (MRI) T1 contrast agent composition including T1 contrast material coated on the surface of a nanoparticle support. The MRI T1 contrast agent composition of the present invention has excellent T1 spin magnetic relaxation effects by modifying the paramagnetic T1 contrast material on the nanoparticle support having a certain diameter such that the paramagnetic T1 contrast material has a certain thickness or less, and thereby remarkably increasing the surface-to-volume ratio of the T1 contrast material. The present invention provides more precise and clear T1 positive contrast images, and is thus useful for highly reliable image diagnosis. | 2016-01-07 |
20160000943 | PHOSPHOLIPID COMPOSITION AND MICROBUBBLES AND EMULSIONS FORMED USING SAME - A composition for stabilizing a fluorocarbon emulsion. That composition includes phosphatidylcholine, phosphatidylethanolamine-PEG, and a cone-shaped lipid. | 2016-01-07 |
20160000944 | PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND - It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [ | 2016-01-07 |
20160000945 | METHODS FOR EVALUATING BRAIN-WIDE PARAVASCULAR PATHWAY FOR WASTE CLEARANCE FUNCTION AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS BASED THEREON - Methods are provided for measuring glio-vascular pathway (“glymphatic system”) function in the brain of a mammal which include performing imaging of the brain and measuring cerebrospinal fluid-interstitial fluid (CSF-ISF) exchange in the brain. The methods can be used to track the exchange between CSF and ISF compartments. An imaging agent is optionally administered intrathecally. The imaging agent can be a negative or positive (paramagnetic) contrast agent and dynamic or contrast-enhanced magnetic resonance imaging (MRI) of the brain can be performed. The imaging agent can be a positron-emitting radionuclide tracer and positron emission tomography (PET) can be performed. Methods for treating diseases or disorders of the mammalian brain are also provided, in which the methods increase or decrease glymphatic clearance. | 2016-01-07 |
20160000946 | RADIOLABELED ANTI-GLYPICAN-3 IMMUNOCONJUGATES FOR IMMUNO-PET IMAGING OF HEPATOCELLULAR CARCINOMA - Provided are immunoconjugate probes useful for detecting hepatocellular carcinoma (HCC) lesions. The probes comprise a glypican-3 (GPC3)-specific monoclonal antibody or fragment thereof conjugated to a radionuclide such as | 2016-01-07 |
20160000947 | Treatment System for Cleaning a Component, in Particular an Implant Part, Contaminated with a Biofilm - A treatment system ( | 2016-01-07 |
20160000948 | STERILIZATION OF CIPROFLOXACIN COMPOSITION - Disclosed herein are methods of making sterilized ciprofloxacin compositions. In some embodiments, the method includes the steps of: (a) forming an aqueous suspension comprising ciprofloxacin particles; (b) heating the aqueous suspension comprising ciprofloxacin particles at a temperature range of from about 100° C. to about 120° C.; and (c) allowing the aqueous suspension comprising ciprofloxacin particles to cool down. Also described herein are otic formulations containing ciprofloxacin formed by the disclosed methods, and therapeutic use of such otic formulation for providing sustained release of ciprofloxacin into the ear for treating various otic disorders and conditions. | 2016-01-07 |
20160000949 | APPARATUS FOR THE GENERATION OF LOW-ENERGY X-RAYS - An X-ray source for producing soft X-rays, the X-ray source comprising: a cathode having an electron-emitting structure supported by a support structure, the electron-emitting structure being at least partially transparent to X-rays within a region bounded by the support structure; an anode having an X-ray emitting surface parallel to the electron-emitting structure of the cathode; and an electrically insulating spacer arranged between the anode and the cathode; wherein the electron-emitting structure of the cathode and the X-ray emitting surface of the anode are arranged such that, in use, the electron-emitting structure is operable to bombard the anode with electrons, causing X-rays to be emitted from the X-ray emitting surface and to pass through the cathode; and wherein the insulating spacer is arranged between the anode and the support structure of the cathode and projects beyond the support structure, across part of the anode, into the said region. | 2016-01-07 |
20160000950 | Small Household Goods Sanitizing Apparatus - An enclosure has a bottom open ended portion that serves to cover any of a variety of household goods. The top surface to the enclosure has a circuit formed of a switch, an ultraviolet (UV) light or lamp and battery to power the UV light or lamp. The UV light projects downward onto the enclosed household goods to sanitize the enclosed goods. | 2016-01-07 |
20160000951 | METHOD AND APPARATUS FOR STERILIZING A SURFACE - Various devices for sterilizing a surface are disclosed. For example, a first device includes an ultraviolet light emitting unit, a processor and a computer-readable medium. The computer-readable medium stores instructions which, when executed by the processor, cause the processor to perform operations. The operations include detecting a proximity of a surface to the ultraviolet light emitting unit and activating the ultraviolet light emitting unit to sterilize the surface in response to the detecting. Another device includes an ultraviolet light emitting unit, a processor and a computer-readable medium. The computer-readable medium stores instructions which, when executed by the processor, cause the processor to perform operations. The operations include storing a location parameter, determining whether location information of the device satisfies the location parameter and activating the ultraviolet light emitting unit when it is determined that the location information of the device satisfies the location parameter. | 2016-01-07 |
20160000952 | Targeted Enzymatic Degradation Of Quorum-Sensing Peptides - Methods and compositions for the treatment of biofilms and/or the inhibition of biofilm formation. In one embodiment, a biofilm is treated and/or biofilm formation is inhibited by a method comprising contacting a biofilm or a surface with a bifunctional ligand comprising a quorum-sensing-peptide-binding region and a protease-binding region, whereby the biofilm is treated and/or biofilm formation on the surface is inhibited. | 2016-01-07 |
20160000953 | Electronic Gadget Disinfection - A solution for disinfecting electronic devices is provided. An ultraviolet radiation source is embedded within an ultraviolet absorbent case. While the electronic device is within the ultraviolet absorbent case, ultraviolent radiation is directed at the electronic device. A monitoring and control system monitors a plurality of attributes for the electronic device, which can include: a frequency of usage for the device, a biological activity at a surface of the device, and a disinfection schedule history for the device. Furthermore, the monitoring and control system can detect whether the device is being used. Based on the monitoring, the monitoring and control system controls the ultraviolet radiation directed at the electronic device. | 2016-01-07 |
20160000954 | BIOLOGICAL INDICATOR FOR MONITORING A LOW-TEMPERATURE STERILIZATION PROCESS - An article and method are provided for assessing the efficacy of a sterilization process. The article comprises an outer container having an interior volume; a dry source of measurable biological activity disposed in the interior volume; and an effective amount of a dry agent for neutralizing a sterilant compound; wherein both the source of measurable biological activity and the agent are in vapor communication with an environment outside the outer container. The method comprises exposing the article to a first sterilant and, optionally, a second sterilant for a period of time and detecting the measurable biological activity. | 2016-01-07 |
20160000955 | Combined Odor Absorption and Insect Repellent Compositions, Treatments, and Methods of Use - Combined insect repellents and odor-reducing compositions are disclosed that use the insect repellent Picaridin [2-(2-hydroxyethyl)-1-piperidine carboxylic acid 1-methylpropyl ester] in combination with the odor-reducer zinc ricinoleate are disclosed, as are methods for using these compositions. The presence of the odor reducer does not reduce the apparent efficacy of the Picaridin, and tends to reduce the odor of the Picaridin itself. | 2016-01-07 |
20160000956 | CONTROLLED INTERMITTENT FRAGRANCE DELIVERY DEVICES AND CARTOMIZER CARTRIDGE FOR USE THEREIN - Fragrance delivery devices, consistent with embodiments of the present disclosure, may be controlled to deliver a fragrance intermittently and/or selectively. A fragrance delivery device generally includes a housing containing a cartomizer for producing a fragrance vapor from a fragrance liquid, and control circuitry for controlling the production of the fragrance vapor in response to a user input. The fragrance delivery device may include a user interface and/or a wireless interface for connecting to a remote control device, such as a smart phone, tablet, or other computing device, to provide the user input. The fragrance delivery device may deliver the fragrance vapor using natural convection and/or by moving air through the device, for example, with a fan. The fragrance delivery device may also include a power source, such as a battery, and/or may include a connection to an external power source. | 2016-01-07 |
20160000957 | Fragrance card with windowed container - This invention is a fragrance card, with an attachment device, located within a container, that incorporates a window, which when removed, allows the fragrance of the impregnated card to be released into the ambient atmosphere. | 2016-01-07 |
20160000958 | A DISPENSING UNIT - A dispensing unit has a base with two or more upwardly projecting side panels hingedly attached thereto. The sides have upper ends which pivot inwardly to a closed position, and outwardly to an open position. One or more removable dispensable compound containers are locatable within the unit, positioned adjacent a relative movable side panel. Each side has a capping projection that is located over and caps the container when the side panel is in a closed position, and which uncap the container when in the open position. When the sides are pivoted outwardly, they permit dispensing of the dispensable compound located in each container. | 2016-01-07 |
20160000959 | AXIAL, TRIPLE-SEPARATION, DIFFUSION APPARATUS AND METHOD - A reservoir containing an essential oil feeds to an eductor injecting a jet forming a plume of air entraining oil droplets. A series of drift chambers act as velocity reducers to alternately slow the flow droplets with entry, and then reaccelerate them upon exit through an exit channel. A micro cyclone separator operates between at least two of the drift chambers, exposing the flow to circumferential direction and centripetal acceleration driving comparatively larger droplets out of the flow away from comparatively finer droplets sufficiently small to remain with the flow of air. Separation of comparatively larger droplets, effectively eliminates “spitting” of liquids that might or rapid drift onto surrounding surfaces. | 2016-01-07 |
20160000960 | DEVICE FOR AIR FILTRATION AND PURIFICATION - Device for air filtration and purification comprising an enclosure for the flow of the air, said enclosure comprising an air inlet opening and an air outlet opening; one or more inner plates arranged inside said enclosure at an inclined angle in respect of the air flow direction, between said air inlet and outlet, and arranged such that the air flows along such inclined inner plate or plates; one or more UV light emitters arranged inside said enclosure to emit UV light over said inner plates and over said air flow; wherein said inner plates are photo-catalytic and are electrostatic precipitators. An embodiment comprises one or more pairs of said inner plates, wherein each pair of inner plates is placed side-by-side transversally to the airflow and in a cross-shape arrangement with the two plates being arranged inclined at 45° from the bottom surface of the enclosure. | 2016-01-07 |
20160000961 | FEMININE HYGIENE ABSORBENT ARTICLES COMPRISING WATER-ABSORBING COMPOSITES - This invention relates to a feminine hygiene absorbent article comprising water-absorbing composites obtainable by foaming an aqueous mixture comprising at least one monoethylenically unsaturated monomer bearing acid groups, at least one crosslinker, at least one initiator and at least one surfactant, contacting the foam obtained with at least one web of synthetic fibers and polymerizing, to the composites themselves and to their use for absorbing aqueous fluids. | 2016-01-07 |
20160000962 | Hemostatic Compositions - A cross linked recombinant gelatin composition for the induction of blood coagulation and hemostasis. | 2016-01-07 |
20160000963 | FORMATION OF SEMI-PERMEABLE POROUS ARTIFICAL SCAB - Pourous semi-ermeable artificial self-attaching scab designed to protect the eroded or injured surfaces. | 2016-01-07 |
20160000964 | BIODEGRADABLE IMPLANT AND METHOD FOR MANUFACTURING SAME - This invention relates to a biodegradable implant including magnesium, wherein the magnesium contains, as impurities, (i) manganese (Mn); and (ii) one selected from the group consisting of iron (Fe), nickel (Ni) and mixtures of iron (Fe) and nickel (Ni), wherein the impurities satisfy the following condition: 0(i)≦5, and an amount of the impurities is 1 part by weight or less but exceeding 0 parts by weight based on 100 parts by weight of the magnesium, and to a method of manufacturing the same. | 2016-01-07 |
20160000965 | CHEMICAL GRADIENTS - In one aspect, apparatuses for providing chemical gradients are described herein. In some embodiments, an apparatus described herein comprises a conduit having a first end and a second end, one or more microchannels disposed in the conduit and extending from the first end toward the second end, and a fiber coiled around the exterior of at least one microchannel, wherein the fiber comprises an active agent that is operable to diffuse into the interior of the microchannel. | 2016-01-07 |
20160000966 | MATERIALS FOR GASTROINTESTINAL OBSTRUCTION PREVENTION - Materials and methods for preventing gastrointestinal obstruction are provided. A peptide comprising between about 7 amino acids and about 32 amino acids in a solution may be introduced to a target site. The peptide may undergo self-organization under physiological conditions and/or in the presence of a cation. | 2016-01-07 |
20160000967 | MEDICAL DEVICE WITH A BIOCOMPATIBLE COATING - An implantable medical device comprising (a) a metallic substrate and (b) a bisphosphonate wherein both phosphorus atoms contained in the bisphosphonate are covalently attached to a same carbon atom. The bisphosphonate continuously coats the external surface of the metallic substrate as monolayer and as outermost layer. At least one phosphonate moiety of the bisphosphonate is covalently and directly bonded to the external surface of the metallic substrate and/or covalently bonded to another molecule of the bisphosphonate in the coating. | 2016-01-07 |
20160000968 | PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME - Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion which has been decellularized and at least one layer of chorion. Also described herein are methods for making and using the tissue grafts. | 2016-01-07 |
20160000969 | Solid Substrates for Promoting Cell and Tissue Growth - This invention provides solid substrates for promoting cell or tissue growth or restored function, which solid substrate is characterized by a specific fluid uptake capacity value of at least 75%, which specific fluid uptake capacity value is determined by establishing a spontaneous fluid uptake value divided by a total fluid uptake value. This invention also provides solid substrates for promoting cell or tissue growth or restored function, which solid substrate is characterized by having a contact angle value of less than 60 degrees, when in contact with a fluid. This invention also provides solid substrates for promoting cell or tissue growth or restored function, which solid substrate is characterized by a substantial surface roughness (Ra) as measured by scanning electron microscopy or atomic force microscopy. The invention also provides for processes for selection of an optimized coral-based solid substrate for promoting cell or tissue growth or restored function and applications of the same. | 2016-01-07 |
20160000970 | Crosslinked Soft Tissue Graft and Methods of Use Thereof - The invention relates to crosslinked soft tissue grafts and methods of use thereof. The invention also relates to methods of preparing the same. | 2016-01-07 |
20160000971 | PLGA/HYDROXYAPATITE COMPOSITE BONE GRAFTS AND METHOD OF MAKING - The present invention involves tissue engineering constructs made from a new composite bone graft material made from biocompatible poly(D,L-lactic-co-glycolic acid) (PLGA) and bioceramic particles exposed on its surface using a gas foaming particle leaching (GF/PL) method and infused with collagen. Methods and apparatus for of forming scaffolds are also disclosed. | 2016-01-07 |
20160000972 | COMPOSITIONS AND METHODS FOR TREATING THE VERTEBRAL COLUMN - The present invention relates to compositions and methods useful for treating structures of the vertebral column, including vertebral bodies. In one embodiment, a method for promoting bone formation in a vertebral body comprising providing a composition comprising a PDGF solution and a biocompatible matrix and applying the composition to at least one vertebral body. Promoting bone formation in a vertebral body, according to some embodiments, can increase bone volume, mass, and/or density leading to an increase in mechanical strength of the vertebral body treated with a composition of the present invention. | 2016-01-07 |
20160000973 | REPORTER SCAFFOLDS - The invention provides for the development of reporter scaffolds comprising sustained release reporter molecules and methods of using these scaffolds to administer therapeutic agent and/or monitor the effect of the transplant on the surrounding tissue or monitoring the status or condition of transplanted cells over time after the scaffold is in place. | 2016-01-07 |
20160000974 | Composite Matrix for Bone Repair Applications - Composite fibrous and non-fibrous matrices of biocompatible, bioactive synthetic polymers and ceramics are described. The composite matrices support bone cell differentiation and may be used alone or with whole bone marrow, isolated mesenchymal stem cells and/or bone grafts for bone repair and bone regeneration. | 2016-01-07 |
20160000975 | LOCAL DELIVERY OF WATER-SOLUBLE OR WATER-INSOLUBLE THERAPEUTIC AGENTS TO THE SURFACE OF BODY LUMENS - A method and device for local delivery of a water-insoluble therapeutic agent to the tissue of a normal or diseased body lumen is disclosed. An expandable structure of a medical disposable device, such as a balloon of a balloon catheter, is coated with a non-durable coating which comprises poly(HEMA) complexed with iodine and has a substantially water-insoluble therapeutic agent dispersed therein. The medical disposable device is inserted into a body lumen, and expanded to contact the non-durable coating against the body lumen and deliver the substantially water-insoluble therapeutic agent to the body lumen tissue. | 2016-01-07 |
20160000976 | METHOD FOR ELECTROSPINNING A GRAFT LAYER - A method for making a graft layer is provided. The graft layer has at least two layers with different porosities. The two layers are applied by electrospinning. The parameters of the electrospinning may be varied when applying the first and second layers in order to achieve different porosities of the first and second layers. | 2016-01-07 |
20160000977 | Drug Composition and Coating - According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization. | 2016-01-07 |
20160000978 | FUNCTIONAL FILM - A functional film that is applied to a surface of a medical apparatus or a biomaterial includes a film of Ti-doped tetrahedral amorphous carbon (ta-C:Ti film). | 2016-01-07 |
20160000979 | BIOACTIVE IMPLANT AND MANUFACTURING METHOD OF BIOACTIVE IMPLANT - There is provided a bioactive implant that has good bioactivity and can firmly maintain adhesion between a metal substrate or a plastic substrate and an apatite layer and abrasion resistance for an extended period of time. The bioactive implant has the apatite layer containing at least crystalline calcium apatite fine particles, an aqueous urethane resin, and a self-emulsifiable isocyanate compound, on the surface of the metal substrate or the plastic substrate. | 2016-01-07 |
20160000980 | PUMP APPARATUS AND METHODS FOR EXPRESSION OF HUMAN BREAST MILK - Improved devices, systems and methods for the expression of milk from a breast are disclosed herein. A device for expression of milk may comprise a peristaltic pump configured to move a fluid to or from a breast interface, so as to apply pressure at the breast interface and thereby express milk from the breast. The peristaltic pump can be removably coupled to a tube carrying the fluid, so as to maintain a separation between the peristaltic pump and the fluidly coupled components of the device. A device for expressing breast milk may further comprise an adjustable breast interface configured to engage and fluidly seal against the human breast. The adjustable breast interface may be manually or automatically adjustable to fluidly seal against a plurality of sizes or shapes of human breasts. | 2016-01-07 |
20160000981 | METHODS AND APPARATUS FOR ABATING NOISE DURING EXPRESSION OF HUMAN BREAST MILK - A system for abating noise during expression of human breast milk includes a noise abatement device and a breast milk expression pump. The noise abatement device may comprise a container configured to receive the breast milk expression pump, the container configured to abate noise generated by the breast milk expression pump disposed within the container. The noise abatement container may comprise one or more sound-absorbing materials or geometries. When the pump is positioned in the noise abatement container, noise from the pump is abated while the pump is operating. | 2016-01-07 |
20160000982 | METHODS AND APPARATUS FOR TRANSFERRING PRESSURE DURING EXPRESSION OF HUMAN BREAST MILK - A device for expression and collection of breast milk includes an actuatable assembly and a breast interface. The breast interface is sized to receive a breast and form a fluid tight seal against the breast. The breast interface includes an expandable membrane disposed within at least a portion of the breast interface. The expandable membrane reversibly deforms in response to actuation of the actuatable assembly, thereby applying vacuum pressure at the breast to express milk. The expandable membrane comprises a plurality of expandable pleats which extend radially outward from a central longitudinal axis of the breast interface. | 2016-01-07 |
20160000983 | Ventricular assist device - The invention relates to a ventricular assist device for intraventricular placement inside a human heart including an anchor element configured to be mounted to the heart in the region of the apex; and a pump connected to the anchor element comprising a preferably tubular housing having an intraventricular inlet and an intraventricular outlet and further comprising a drive for driving a rotor arranged within the housing, thereby providing pulsatile flow acceleration in the left ventricle synchronized with the heart beat and according to volume requirements in the left ventricle. | 2016-01-07 |
20160000984 | DIALYSIS IMPLANT AND METHODS OF USE - A device and methods for treating renal failure are disclosed. One embodiment of the device is an implantable peritoneal dialysis device. When in use, the device can have a semi-permeable reservoir implanted in the peritoneal cavity. The reservoir can receive blood waste and drain through one or more conduits, via a pump, to the biological bladder. Solids and/or a solution benefiting dialysis can be pumped to the reservoir and/or implanted in the peritoneal cavity. | 2016-01-07 |
20160000985 | EXTRAVASCULAR DEVICES SUPPORTING AN ARTERIOVENOUS FISTULA - A medical device includes a curved tubular body configured for being used as an extravascular device to support vein maturation following the formation of an arteriovenous fistula. The tubular body is curved. The tubular body has an entrance angle of less than about 40 degrees to improve blood flow from the artery into the vein. And the tubular body includes a cuff or edge at the proximal end to stabilize the tubular body at the fistula. | 2016-01-07 |
20160000986 | BLOOD OXYGENATION SYSTEM - A blood oxygenation system which prevents transmigration of blood to gaseous oxygen circuitry. The system includes a blood circuit, an oxygen supply circuit, an oxygen-blood interface in which gaseous oxygen is absorbed into the blood, and an oxygen disposal circuit for disposing of unused oxygen. The oxygen-blood interface is arranged to prevent transmigration of blood into the oxygen circuit. The blood circuit includes a pump and a blood de-aerator. The oxygen supply circuit includes an oxygen supply, an ozone generator, and an ozone destructor. A silica gel trap in the oxygen disposal circuit separates O | 2016-01-07 |
20160000987 | DEVICE AND METHOD FOR PURIFYING VIRALLY INFECTED BLOOD - The present invention relates to a method for using lectins that bind to pathogens having surface glycoproteins or fragments thereof which contain glycoproteins, to remove them from infected blood or plasma or other fluids in an extracorporeal setting. Accordingly, the present invention provides a methods and devices for reducing viral load or plaque forming units in blood or plasma from one or more infected individuals. A preferred embodiment of the method comprises passing the blood or plasma through a porous hollow fiber membrane wherein lectin molecules are disposed proximate to the membrane, collecting pass-through blood or plasma and optionally reinfusing the pass-through blood or plasma into the individual. Additionally, the present invention provides a methods and devices for the reduction of plaque forming units, cleared more rapidly and more efficiently than overall viral load. | 2016-01-07 |
20160000988 | TUBE FOR EXTRA-CORPOREAL CIRCUIT WITH DOUBLE CONNECTOR - The present invention relates to a double connector for a tubular insert, intended to connect an extra-corporeal circuit to a peristaltic pump. The double connector comprises: a first channel with an axis a | 2016-01-07 |
20160000989 | CARBON DIOXIDE REMOVAL SYSTEM - An extracorporeal blood treatment system including a gas exchange module operatively associated with a gas supply unit and optional pump for removing CO | 2016-01-07 |
20160000990 | DIALYSIS MACHINE - A dialysis machine which includes a preparation system comprising a main line for the dialysis liquid, several supply lines for respective concentrates opening at said main line is disclosed. At a point behind each orifice a respective mixing chamber is arranged and after the latter a respective conductivity probe is disposed. Downstream of the last conductivity probe, a shared pump is arranged. The negative pressure in the main line is adjusted via a pressure control valve which is arranged upstream of the first orifice in the main line. Furthermore, a proportional valve or a digital switching valve is disposed for metering the various concentrates in each supply line. The pressure control valve and the proportional valves or switching valves are controlled in electromagnetic fashion by a central electronic control unit. | 2016-01-07 |
20160000991 | DEVICE AND METHOD FOR RAPID ASPIRATION AND COLLECTION OF BODY TISSUE FROM WITHIN AN ENCLOSED BODY SPACE - Device and method for rapid extraction of body tissue from an enclosed body cavity. Hollow entry cannula with optional core element provides entry into body tissue space such as bone marrow. Aspiration cannula is inserted through cannula into body tissue and is manipulated to advance directionally through body cavity. Optional stylet within aspiration cannula aids in advancing aspiration cannula through body tissue and is removed to facilitate extraction of body tissue through the aspiration cannula. Inlet openings near distal tip of aspiration cannula allow tissue aspiration, with negative pressure source at proximal end of aspiration cannula providing controlled negative pressure. Aspiration cannula may be withdrawn and its path adjusted for multiple entries through the same entry point, following different paths through tissue space for subsequent aspiration of more tissue. | 2016-01-07 |
20160000992 | NEEDLE ASSEMBLY MAGAZINE - Described is a needle assembly magazine ( | 2016-01-07 |
20160000993 | STERILE TRANSFER OF FLUID - A syringe rack securable to a surface of a fixture and configured for facilitating a sterile transfer of fluid from a non-sterile environment to a sterile environment. The syringe rack includes a securing portion and a syringe-receiving station. The syringe-receiving portion is coupled to the securing portion and configured to receive the syringe in a selectively releasable coupling arrangement where the syringe is oriented such that an opening in a barrel of a syringe projects away from the fixture when the syringe is received by the syringe-receiving station and when the securing portion is secured to the surface of the fixture. | 2016-01-07 |
20160000994 | INTERFACE FOR MEDICAL INFUSION PUMP - An apparatus for indicating acceptable programmable dosing of an infusate, for delivery by a medical infusion pump programmable with a protocol library defining at least one dosing range of the infusate is disclosed. A method of indicating acceptable programmable dosing of an infusate, for delivery by a medical infusion pump programmable with a protocol library defining at least one dosing limit of the infusate is also disclosed. | 2016-01-07 |
20160000995 | TRANSFORMABLE INTRAVENOUS POLE AND BOOM COMBINATION AND METHOD THEREOF - An intravenous (IV) pole docking system for supporting medical equipment having a mast engaged to a base, the base having legs to support the mast and a lifting mechanism engaged to the base and the mast for moving the base along the mast in combination with an extension arm meant to reduce the IV pole footprint. The boom/IV pole system can reduce excess obstacles in and around hospital bed, surgical rooms and the like. | 2016-01-07 |
20160000996 | APPARATUS FOR RECEIVING A SYRINGE IN A FLUID-DISPENSING APPARATUS AND A METHOD FOR SAME AND USE OF SUCH A RECEPTACLE - The invention relates to a device and a method for receiving of a syringe in a fluid-dispensing apparatus without play, said apparatus having at least two elastically prestressable clamping means which grip the plunger flange of a syringe, such that an elongated hole is provided for each clamping means, the clamping means sliding in the elongated hole and thus executing a rotational movement and a translatory movement at the same time during the gripping operation. In addition, the invention relates to a method for doing so and a device having such an apparatus. | 2016-01-07 |
20160000997 | MANAGEMENT OF PENDING MEDICATION ORDERS - Pending medication orders are presented on the controller of an infusion pump to which a patient has been identified. All pending medication orders are displayed on the screen of the controller and any may be selected by the clinician. Selecting a pending order at the controller that involves an infusion to the patient also results in automatic programming of the infusion pump in accordance with that order. Selection of an oral medication at the controller results, as does selection of any other order, in notification to the healthcare facility server that the order is being administered. Such notification resolves open controlled item transactions as well as provides information that may be relevant to a patient's EMAR. Selection of a pending order may occur manually or automatically through identification of a medication. | 2016-01-07 |
20160000998 | Glucagon Administration System and Methods - Some embodiments a glucagon administration system can provide a suggested glucagon dosage based on one or more particular parameters (e.g., the user's recent blood glucose characteristics, a glucagon sensitivity value of the user, and other parameters). In some circumstances, the glucagon administration system can receive information indicative of the user's blood glucose level and suggest a glucagon dosage that is at least partially dependent upon a previously stored glucagon sensitivity for the user. | 2016-01-07 |
20160000999 | INTERNAL CAM METERING PUMP - A micropump according to the invention uses an eccentric cam member rotating within a pump housing to sequentially open and close valves in the pump housing to withdraw fluid from a reservoir and provide metered amounts of the fluid to a cannula port for administration to a patient. The micropump may be used in a disposable pump for continuous infusion of medication such as insulin. | 2016-01-07 |
20160001000 | SYSTEMS AND METHODS USING ESTIMATED GLOMERULAR FILTRATION RATES OF THE KIDNEYS IN THE NON-STEADY STATE - A system and method of determining the estimated glomerular filtration rate of the kidneys of a patient. The system and method obtains patient medical data, determines constants based on the patient medical data and using exactly one of the MDRD equation or the Cockroft-Gault equation, and determines the estimated glomerular filtration rate based on a relationship of measured creatinine levels and the determined constants. The estimated glomerular filtration rate is used to determine the dose of a medication of a type filtered by the kidneys, determine a temporal correlation of the introduction of a drug into a patient with changes in kidney function, determine the administration rate for dosing intravenous fluids, determine the efficacy of a medical treatment, and determine kidney function after transplantation or injury. | 2016-01-07 |
20160001001 | VENTILATORY ASSIST DEVICE - A respiratory support device ( | 2016-01-07 |
20160001002 | DEVICE FOR DRUG DELIVERY - Delivery of more than one therapeutic fluid as a means to control symptoms of a health conditions is disclosed. More than one therapeutic fluid may be dispensed from more than one reservoir and delivered to a user's body via one or more cannula that penetrate the skin. The therapeutic fluids may be delivered by action of one or more pumping mechanisms that may be controlled by a processor in a portable, ambulatory device. The therapeutic fluids may optionally be insulin and one or more of an amylin analog, pramlintide acetate and an exenatide, and the health condition may optionally be diabetes. This device can be used in combination with a glucometer. | 2016-01-07 |
20160001003 | SYRINGE FILLING AND PACKAGING SYSTEM FOR HOSPITAL PHARMACIES - A semi-automated system ( | 2016-01-07 |
20160001004 | DELAY MECHANISM SUITABLE FOR COMPACT AUTOMATIC INJECTION DEVICE - A delay mechanism for an automatic injection device having a housing and a medication filled syringe. The delay mechanism includes a shuttle, a follower, a damping compound, at least one biasing member, and a biased plunger element. When moved in the device housing from a first location to a second location, the biased plunger element is adapted to drive the syringe piston within syringe barrel to force medication through the syringe needle for an injection. The follower, when the plunger element is so moved, is freed to move, under urging of the at least one biasing member, from a first position on the housing toward a second position to thereby move the shuttle for retracting the syringe needle into the housing after injection. The damping compound dampens or slows rotation of the follower as the follower moves from the first position toward the second position. | 2016-01-07 |
20160001005 | AUTO-INJECTOR FOR EPINEPHRINE INJECTION - A reloadable auto injector for epinephrine injection is provided. The reloadable auto injector has a separate needle insertion and medicine injection drivers ( | 2016-01-07 |
20160001006 | SYRINGE ASSEMBLY, SYRINGE ASSEMBLY PACKAGE BODY, SEAL CAP FOR BARREL, AND PREFILLED SYRINGE - A syringe assembly includes a barrel, and a seal cap mounted to the barrel. The seal cap includes a closed distal end portion, an open proximal end portion, a hollow portion including a barrel end storage portion configured to store a barrel end portion, and a puncture needle storage portion extending from the barrel end storage portion, an insertion allowing portion configured to receive a puncture needle tip of a puncture needle guided to the distal end of the puncture needle storage portion, and a projection portion formed on an inner surface of the barrel end storage portion. The projection portion has a top portion, a distal inclined portion, and a proximal inclined portion extending from the top portion toward the open proximal end portion. A non-stick surface for inhibiting sticking to a barrel end portion of the barrel is formed on an inner surface of the projection portion. | 2016-01-07 |